HORSHAM, Pa., Nov. 4, 2015 /PRNewswire/ -- Janssen Biotech, Inc. announced today that more than 35 abstracts from the Janssen Pharmaceutical Companies will be presented at the 2015 American College of Rheumatology (ACR) annual meeting. Data from the rheumatology portfolio of both injection and infusion biologic treatment options will include efficacy and safety data from Phase 3 studies for STELARA® (ustekinumab), Phase 3 health-related quality of life data for SIMPONI ARIA® (golimumab for infusion), long-term outcomes data for SIMPONI® (golimumab), an ethnographic study investigating shared decision-making between rheumatologists and rheumatoid arthritis (RA)...
↧